Global Pharma Deal Value Rises to $18.3 Bn in July 2025: Reports

While the number of deals fell below the 12-month average of 95, the total value surpassed the average monthly deal value of $13.2 billion seen between July 2024 and June 2025.

The global pharmaceutical industry recorded 69 deals totaling $18.3 billion in July 2025, according to GlobalData.

While the number of deals fell below the 12-month average of 95, the total value surpassed the average monthly deal value of $13.2 billion seen between July 2024 and June 2025.

Driving the majority of July’s deal value were transactions involving Merck, Nordic Capital, and Sanofi, which collectively accounted for 79 per cent of the month’s total.

Merck & Co Inc announced a $10 billion acquisition of Verona Pharma Plc, a biopharmaceutical company focused on respiratory diseases, making it the largest transaction of the month.

In another major development, Innosera ApS, a newly formed entity backed by Nordic Capital Fund, agreed to acquire Bavarian Nordic AS, a global vaccine company, for $2.9 billion.

Sanofi also announced it would acquire Vicebio Ltd, a clinical-stage biopharmaceutical company developing multi-pathogen vaccines, in a $1.5 billion deal.

While mergers and acquisitions saw strong numbers in value, venture capital activity declined. July recorded 90 VC deals valued at $1.9 billion, down 25 per cent compared to July 2024 and below the 12-month average of 97 deals worth $2.5 billion.

Among the top VC deals, MapLight Therapeutics Inc raised $372.5 million in a Series D round to advance the development of ML-007C-MA and other pipeline programs.

Artbio Inc secured $132 million in Series B funding to expand its Alpha Radioligand therapy pipeline and bolster manufacturing capabilities.

Avalyn Pharma Inc raised $100 million in Series D financing to continue developing inhaled therapies for pulmonary fibrosis.

Stay tuned for more such updates on Digital Health News